(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
From Representative to Business visionary: Private issue Victories - 2Mount Everest Climbers 'Poisoned' by Guides Prompting Mass Helicopter Rescues in $20 Million Insurance Fraud Scheme, Police Say
- 3Zelensky confidant dismissed from further posts amid bribery scandal
- 4Europe: 4 Urban communities for a Paramount Social Experience
- 5Beyond the habitable zone: Exoplanet atmospheres are the next clue to finding life on planets orbiting distant stars
- Pain at the pump for Hampton Roads residents
- A 3-limbed Kemp's ridley sea turtle is now being tracked at sea by satellite
- Nitty gritty Manual for Picking Agreeable Tennis shoes
- IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
- Dark matter may be made of pieces of giant, exotic objects — and astronomers think they know how to look for them
- Iran slams UN nuclear watchdog for failing to condemn Bushehr attacks
- Embrace the Outside: Exercises and Entertainment
- Police break up illegal chicken slaughter in Germany
- New York to require social media platforms to display mental health warnings
